Form 4: Nurix Therapeutics Executive Granted Stock Options and Restricted Stock Units
SEC Form 4 Filing
Christine Ring, Chief Legal Officer of Nurix Therapeutics, received stock options and restricted stock units (RSUs) on February 11, 2025, according to a Form 4 filing.
Summary
- Christine Ring, the Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), was granted stock options and restricted stock units (RSUs) on February 11, 2025.
- The stock option grants Ring the right to buy 75,000 shares of common stock at an exercise price of $17.12 per share.
- These options vest monthly, starting March 11, 2025, and will be fully vested by February 10, 2028, contingent upon continued service to the company.
- Ring also received 34,300 RSUs, each representing a contingent right to receive one share of Nurix Therapeutics' common stock.
- The RSUs will vest quarterly over three years, beginning July 30, 2025, also subject to continued service.
- Following vesting, shares of common stock will be delivered to Ring.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, incentivizing the executive and aligning their interests with shareholders. There are no immediate negative implications.
Positives
- The grant of stock options and RSUs aligns the Chief Legal Officer's interests with those of the shareholders.
- The vesting schedules incentivize continued service and contribution to the company's success.
Industry Context
Stock option and RSU grants are common practices in the biotechnology industry to attract, retain, and incentivize key executives.
Comparison to Industry Standards
- Stock option grants and RSU awards are standard compensation components for executives in publicly traded biotechnology companies.
- Companies like Amgen, Gilead Sciences, and Biogen routinely use similar equity-based compensation to align executive incentives with shareholder value.
- The vesting schedules (monthly for options, quarterly for RSUs) are also typical in the industry, encouraging long-term commitment.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align executive interests with company performance.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 02/11/2025 | Date of the transaction (grant of stock options and RSUs). |
| 03/11/2025 | Start date for monthly vesting of stock options. |
| 07/30/2025 | Start date for quarterly vesting of RSUs. |
| 02/10/2028 | Date when stock options are fully vested. |
| 02/10/2035 | Expiration date of the stock options. |
| 02/13/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.